全文获取类型
收费全文 | 903篇 |
免费 | 53篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 29篇 |
妇产科学 | 11篇 |
基础医学 | 117篇 |
口腔科学 | 2篇 |
临床医学 | 60篇 |
内科学 | 163篇 |
皮肤病学 | 7篇 |
神经病学 | 59篇 |
特种医学 | 56篇 |
外科学 | 267篇 |
综合类 | 5篇 |
预防医学 | 16篇 |
眼科学 | 92篇 |
药学 | 52篇 |
肿瘤学 | 17篇 |
出版年
2022年 | 4篇 |
2021年 | 16篇 |
2020年 | 9篇 |
2019年 | 10篇 |
2018年 | 23篇 |
2017年 | 18篇 |
2016年 | 16篇 |
2015年 | 24篇 |
2014年 | 27篇 |
2013年 | 33篇 |
2012年 | 49篇 |
2011年 | 48篇 |
2010年 | 34篇 |
2009年 | 21篇 |
2008年 | 42篇 |
2007年 | 39篇 |
2006年 | 54篇 |
2005年 | 44篇 |
2004年 | 59篇 |
2003年 | 55篇 |
2002年 | 53篇 |
2001年 | 35篇 |
2000年 | 35篇 |
1999年 | 38篇 |
1998年 | 11篇 |
1997年 | 8篇 |
1996年 | 4篇 |
1993年 | 3篇 |
1992年 | 7篇 |
1991年 | 7篇 |
1990年 | 5篇 |
1989年 | 7篇 |
1988年 | 3篇 |
1987年 | 9篇 |
1986年 | 5篇 |
1985年 | 6篇 |
1984年 | 3篇 |
1979年 | 6篇 |
1971年 | 3篇 |
1939年 | 3篇 |
1937年 | 3篇 |
1930年 | 6篇 |
1926年 | 7篇 |
1924年 | 8篇 |
1923年 | 2篇 |
1921年 | 3篇 |
1919年 | 3篇 |
1913年 | 2篇 |
1907年 | 2篇 |
1904年 | 2篇 |
排序方式: 共有956条查询结果,搜索用时 15 毫秒
1.
Die Anaesthesiologie - Eine junge Patientin erleidet während der Anlage einer axillären Plexusblockade einen generalisierten Krampfanfall. Die Mechanismen, im Wesentlichen die vermutlich... 相似文献
2.
3.
4.
Matthew Cooper Maurizio Salvadori Klemens Budde Frederic Oppenheimer Hans Sollinger Martin Zeier 《Transplantation reviews (Orlando, Fla.)》2012,26(4):233-240
Mycophenolate mofetil (MMF), a mycophenolic acid (MPA) formulation, has improved both short- and long-term outcomes following renal transplantation, but is often associated with gastrointestinal (GI) complications that can lead to dose reduction or discontinuation, potentially jeopardizing patient outcomes. Enteric-coated mycophenolate sodium (EC-MPS) delivers equivalent MPA exposure to MMF and offers the potential to reduce GI burden (while maintaining patient safety). Here we review the efficacy of EC-MPS compared with MMF in renal transplant patients in terms of biopsy-proven acute rejection and graft loss, and examine the use of EC-MPS in newer regimens such as intensified dosing and calcineurin inhibitor minimization. 相似文献
5.
F. Vincenti H. Tedesco Silva S. Busque P. O’Connell J. Friedewald D. Cibrik K. Budde A. Yoshida S. Cohney W. Weimar Y. S. Kim N. Lawendy S.‐P. Lan E. Kudlacz S. Krishnaswami G. Chan 《American journal of transplantation》2012,12(9):2446-2456
In this Phase 2b study, 331 low‐to‐moderate risk de novo kidney transplant patients (approximately 60% deceased donors) were randomized to a more intensive (MI) or less intensive (LI) regimen of tofacitinib (CP‐690, 550), an oral Janus kinase inhibitor or cyclosporine (CsA). All patients received basiliximab induction, mycophenolic acid and corticosteroids. Primary endpoints were: incidence of biopsy‐proven acute rejection (BPAR) with a serum creatinine increase of ≥0.3 mg/dL and ≥20% (clinical BPAR) at Month 6 and measured GFR at Month 12. Similar 6‐month incidences of clinical BPAR (11%, 7% and 9%) were observed for MI, LI and CsA. Measured GFRs were higher (p < 0.01) at Month 12 for MI and LI versus CsA (65 mL/min, 65 mL/min vs. 54 mL/min). Fewer (p < 0.05) patients in MI or LI developed chronic allograft nephropathy at Month 12 compared with CsA (25%, 24% vs. 48%). Serious infections developed in 45%, 37% and 25% of patients in MI, LI and CsA, respectively. Anemia, neutropenia and posttransplant lymphoproliferative disorder occurred more frequently in MI and LI compared with CsA. Tofacitinib was equivalent to CsA in preventing acute rejection, was associated with improved renal function and less chronic allograft histological injury, but had side‐effects at the doses evaluated. 相似文献
6.
N. Flechtenmacher F. Kmmerer R. Dittmer U. Budde P. Michels J. Rther B. Eckert 《AJNR. American journal of neuroradiology》2015,36(10):1953
BACKGROUND AND PURPOSE:Clopidogrel resistance is blamed for thromboembolic complications in neurovascular stent placement. Platelet-function assays are weakly standardized. The aim of this study was to correlate the results of 3 different platelet-inhibition measurements (from light transmission aggregometry, the VerifyNow P2Y12 test, and the Multiplate analyzer) and their relation to periprocedural thromboembolic complications in elective neurovascular stent placement.MATERIALS AND METHODS:Clopidogrel resistance was determined on the day of the intervention according to predefined platelet reactivity cutoff values. All 3 tests were performed in 103 consecutive neurovascular stent-placement procedures in 97 patients (extracranial, n = 77; intracranial, n = 26).RESULTS:The clopidogrel resistance rates were 47.6% (light transmission aggregometry), 50.5% (VerifyNow), and 35.9% (Multiplate). In 67% of the patients, clopidogrel resistance was present according to at least one method. The correlations of qualitative results that classified a patient as responsive or resistant to clopidogrel were 67.9% for light transmission aggregometry with VerifyNow, 77.7% for light transmission aggregometry with the Multiplate, and 66% for VerifyNow with the Multiplate. Periprocedural thromboembolic complications (n = 9) occurred more frequently in patients who were determined by all 3 methods to be clopidogrel resistant. The difference was most pronounced with light transmission aggregometry (complication rates, 14.4% [clopidogrel-resistant patients] vs 3.7% [clopidogrel-responsive patients]). Sensitivity and specificity rates of clopidogrel resistance in relation to embolic complications were, respectively, 78% and 55% for light transmission aggregometry, 67% and 51% for VerifyNow, and 44% and 67% for the Multiplate.CONCLUSIONS:Clopidogrel resistance is a frequent finding in patients who undergo neurovascular stent placement. The correlations among the different testing methods are only modest and differ considerably. Light transmission aggregometry results seem to correlate with thromboembolic complications more accurately than with VerifyNow and Multiplate point-of-care methods.In neurovascular procedures, especially the placement of a stent into an extracranial or intracranial artery, clopidogrel resistance is associated with an increased risk of thromboembolic complications.1–5 In elective neurovascular stent placement, preprocedural testing of platelet inhibition is increasingly performed to identify patients with clopidogrel resistance. However, test result standards for clopidogrel resistance have not been established, and strong clinical evidence that supports the idea that the results of such tests definitively alter clinical outcomes is still lacking. Light transmission aggregometry (LTA) is considered the criterion-standard test method, but standard values have not yet been established. LTA requires a preparation time of 2 hours, whereas point-of-care methods such as the VerifyNow P2Y12 assay (Accumetrics, San Diego, California) and impedance aggregometry using a Multiplate analyzer (Dynabyte, Munich, Germany) offer periprocedural test results within minutes in the operating suite.6A study comparing LTA with point-of-care measurements in percutaneous coronary intervention has shown only modest agreement among the different tests.7 In neurovascular procedures, clopidogrel resistance has been investigated with various methods. However, a comparison of different test methods to determine the correlation of their results with the occurrence of embolic complications has not yet been performed in the clinical context of neurovascular stent placement.The purpose of this study was to determine the correlation of platelet inhibition with clopidogrel according to 3 different testing methods and the association of clopidogrel resistance with thromboembolic complications in elective neurovascular stent placement. 相似文献
7.
8.
9.
10.